{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T00:19:45Z","timestamp":1721261985033},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,17]]},"DOI":"10.7759\/cureus.64753","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T18:44:57Z","timestamp":1721241897000},"source":"Crossref","is-referenced-by-count":0,"title":["Beyond the Surface: Unveiling Hidden Hurdles to Primary Biliary Cholangitis Care"],"prefix":"10.7759","author":[{"given":"Omar","family":"Shamaa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdul","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lora","family":"Rupp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheri","family":"Trudeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017, 67:145-72. 10.1016\/j.jhep.2017.03.022","journal-title":"J Hepatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1575","article-title":"Pharmacokinetics, safety, and tolerability of orally administered ursodeoxycholic acid in patients with Parkinson's disease\u2014a pilot study","volume":"60","author":"Sathe AG","year":"2020","unstructured":"Sathe AG, Tuite P, Chen C, et al.. Pharmacokinetics, safety, and tolerability of orally administered ursodeoxycholic acid in patients with Parkinson's disease\u2014a pilot study. J Clin Pharmacol. 2020, 60:744-50. 10.1002\/jcph.1575","journal-title":"J Clin Pharmacol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199405123301903","article-title":"Ursodiol for the long-term treatment of primary biliary cirrhosis","volume":"330","author":"Poupon RE","year":"1994","unstructured":"Poupon RE, Poupon R, Balkau B. Ursodiol for the long-term treatment of primary biliary cirrhosis. N Engl J Med. 1994, 330:1342-7. 10.1056\/NEJM199405123301903","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000000512","article-title":"Ursodeoxycholic acid treatment preferentially improves overall survival among African Americans with primary biliary cholangitis","volume":"115","author":"Gordon SC","year":"2020","unstructured":"Gordon SC, Wu KH, Lindor K, et al.. Ursodeoxycholic acid treatment preferentially improves overall survival among African Americans with primary biliary cholangitis. Am J Gastroenterol. 2020, 115:262-70. 10.14309\/ajg.0000000000000512","journal-title":"Am J Gastroenterol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2017.10.018","article-title":"Factors associated with prevalence and treatment of primary biliary cholangitis in United States health systems","volume":"16","author":"Lu M","year":"2018","unstructured":"Lu M, Li J, Haller IV, et al.. Factors associated with prevalence and treatment of primary biliary cholangitis in United States health systems. Clin Gastroenterol Hepatol. 2018, 16:1333-41. 10.1016\/j.cgh.2017.10.018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1201\/9781315139470","article-title":"Classification and regression trees","author":"Breiman L","year":"1984","unstructured":"Breiman L, Friedman J, Stone CJ. Classification and regression trees. Chapman and Hall, New York (NY); 1984. 10.1201\/9781315139470"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1996.v110.pm8613058","article-title":"Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis","volume":"110","author":"Lindor KD","year":"1996","unstructured":"Lindor KD, Therneau TM, Jorgensen RA, Malinchoc M, Dickson ER. Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis. Gastroenterology. 1996, 110:1515-8. 10.1053\/gast.1996.v110.pm8613058","journal-title":"Gastroenterology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199105303242204","article-title":"A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis","volume":"324","author":"Poupon RE","year":"1991","unstructured":"Poupon RE, Balkau B, Eschw\u00e8ge E, Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med. 1991, 324:1548-54. 10.1056\/NEJM199105303242204","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2017.12.033","article-title":"Increasing prevalence of primary biliary cholangitis and reduced mortality with treatment","volume":"16","author":"Lu M","year":"2018","unstructured":"Lu M, Zhou Y, Haller IV, et al.. Increasing prevalence of primary biliary cholangitis and reduced mortality with treatment. Clin Gastroenterol Hepatol. 2018, 16:1342-50. 10.1016\/j.cgh.2017.12.033","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.31880","article-title":"Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients","volume":"122","author":"Corpechot C","year":"2002","unstructured":"Corpechot C, Carrat F, Poupon R, Poupon RE. Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients. Gastroenterology. 2002, 122:652-8. 10.1053\/gast.2002.31880","journal-title":"Gastroenterology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30145","article-title":"Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases","volume":"69","author":"Lindor KD","year":"2019","unstructured":"Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2019, 69:394-419. 10.1002\/hep.30145","journal-title":"Hepatology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-315259","article-title":"The British Society of Gastroenterology\/UK-PBC primary biliary cholangitis treatment and management guidelines","volume":"67","author":"Hirschfield GM","year":"2018","unstructured":"Hirschfield GM, Dyson JK, Alexander GJ, et al.. The British Society of Gastroenterology\/UK-PBC primary biliary cholangitis treatment and management guidelines. Gut. 2018, 67:1568-94. 10.1136\/gutjnl-2017-315259","journal-title":"Gut"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000002268","article-title":"The impact of undiagnosed primary biliary cholangitis","volume":"33","author":"Garrido I","year":"2021","unstructured":"Garrido I, Liberal R, Cardoso MJ, Macedo G. The impact of undiagnosed primary biliary cholangitis. Eur J Gastroenterol Hepatol. 2021, 33:e1027-31. 10.1097\/MEG.0000000000002268","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2020.07.029","article-title":"Cost of illness of primary biliary cholangitis - a population-based study","volume":"53","author":"Gerussi A","year":"2021","unstructured":"Gerussi A, Restelli U, Croce D, Bonfanti M, Invernizzi P, Carbone M. Cost of illness of primary biliary cholangitis - a population-based study. Dig Liver Dis. 2021, 53:1167-70. 10.1016\/j.dld.2020.07.029","journal-title":"Dig Liver Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1314","article-title":"Burden of primary biliary cholangitis among inpatient population in the United States","volume":"3","author":"Shahab O","year":"2019","unstructured":"Shahab O, Sayiner M, Paik J, Felix S, Golabi P, Younossi ZM. Burden of primary biliary cholangitis among inpatient population in the United States. Hepatol Commun. 2019, 3:356-64. 10.1002\/hep4.1314","journal-title":"Hepatol Commun"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2020.00006","article-title":"Hispanic patients with primary biliary cholangitis have decreased access to care compared to non-Hispanics","volume":"8","author":"Rabiee A","year":"2020","unstructured":"Rabiee A, Polanco NA, Vara AF, Levy C. Hispanic patients with primary biliary cholangitis have decreased access to care compared to non-Hispanics. J Clin Transl Hepatol. 2020, 8:391-6. 10.14218\/JCTH.2020.00006","journal-title":"J Clin Transl Hepatol"},{"key":"ref17","article-title":"Primary biliary cholangitis with normal alkaline phosphatase - an entity challenging current guidelines","volume":"74","author":"Garrido IM","year":"2021","unstructured":"Garrido IM, Liberal R, Macedo G. Primary biliary cholangitis with normal alkaline phosphatase - an entity challenging current guidelines. Hepatology. 2021, 74:776-7.","journal-title":"Hepatology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/242267-beyond-the-surface-unveiling-hidden-hurdles-to-primary-biliary-cholangitis-care","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T18:45:00Z","timestamp":1721241900000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/242267-beyond-the-surface-unveiling-hidden-hurdles-to-primary-biliary-cholangitis-care"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,17]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.64753","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,17]]}}}